Country: Canada
Language: English
Source: Health Canada
DIFLUCORTOLONE VALERATE
GLAXOSMITHKLINE INC
D07AC06
DIFLUCORTOLONE
0.1%
CREAM
DIFLUCORTOLONE VALERATE 0.1%
TOPICAL
3G/30G/60G
Prescription
ANTI-INFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0115864001; AHFS:
CANCELLED POST MARKET
2016-09-30
_ _ _Page 1 of 19_ PRODUCT MONOGRAPH PR NERISONE ® (DIFLUCORTOLONE VALERATE) Oily Cream 0.1% w/w GSK Standard Topical Corticosteroid GlaxoSmithKline Inc. 7333 Mississauga Road Mississauga, Ontario L5N 6L4 Date of Revision: January 26, 2017 Submission Control No: 200095 _©2017 GSK Inc., All Rights Reserved _ _NERISONE is a trademark of Bayer Schering Pharma Aktiengesellschaft, used under license by GSK Inc. _ _ _ _ _ _Page 2 of 19_ TABLE OF CONTENTS _ _ _ _ PAGE PART I: HEALTH PROFESSIONAL INFORMATION................................................... 3 SUMMARY PRODUCT INFORMATION ................................................................... 3 INDICATIONS AND CLINICAL USE ......................................................................... 3 CONTRAINDICATIONS .............................................................................................. 3 WARNINGS AND PRECAUTIONS ............................................................................. 4 ADVERSE REACTIONS ............................................................................................... 8 DRUG INTERACTIONS ............................................................................................... 8 DOSAGE AND ADMINISTRATION ........................................................................... 9 ACTION AND CLINICAL PHARMACOLOGY ....................................................... 10 STORAGE AND STABILITY ..................................................................................... 11 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................ 11 PART II: SCIENTIFIC INFORMATION ........................................................................ 13 PHARMACEUTICAL INFORMATION ..................................................................... 13 REFERENCES ............................................................................................................. 16 PART III: CONSUMER INFORMATION ...................................................................... 17 _ _ Read the complete document